|
|
2016 Featured Talks » Biomarker analysis and clinical response in patients with B-cell malignancies treated with anti-CD19 CAR T-cell therapy
Tony Polverino from MCC Industry Relations on Vimeo.
Tony Polverino, PhD
Vice President, Research
Kite Pharma
Dr. Polverino obtained my PhD at Flinders University in Adelaide Australia where he studied the role of Ras oncogenes in modulating intracellular calcium levels in cells. His post-doctoral studies were in the laboratory of Dr. Michael Wigler at the Cold Spring Harbor Laboratories where he helped establish that the Ste20/PAK family of kinases as key mediators of Ras signaling. In 1994 he joined Amgen and explored pathways to modulate apoptotic and angiogenesis pathways. He was the program leader for the AMG 706 program, an oral multi-kinase inhibitor that potently inhibits angiogenesis by selectively inhibiting VEGF, PDGF and Kit receptors. In 2011 he was appointed head of the Therapeutic Innovation Unit. In 2015 he joined Kite Pharma as the Vice President of Research responsible for the discovery and development of novel chimeric antigen receptors.
|
